Home/Filings/4/0000950170-24-083303
4//SEC Filing

Kirn David 4

Accession 0000950170-24-083303

CIK 0001650648other

Filed

Jul 11, 8:00 PM ET

Accepted

Jul 12, 5:46 PM ET

Size

13.1 KB

Accession

0000950170-24-083303

Insider Transaction Report

Form 4
Period: 2024-07-10
Kirn David
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-07-10$14.42/sh+11,653$168,0361,070,806 total
  • Sale

    Common Stock

    2024-07-10$22.49/sh12,923$290,5981,059,153 total
  • Exercise/Conversion

    Stock Option (Right To Buy)

    2024-07-101,270148,730 total
    Exercise: $15.78Exp: 2032-01-31Common Stock (1,270 underlying)
  • Exercise/Conversion

    Common Stock

    2024-07-10$15.78/sh+1,270$20,0411,072,076 total
  • Exercise/Conversion

    Stock Option (Right To Buy)

    2024-07-1011,653565,417 total
    Exercise: $14.42Exp: 2033-12-10Common Stock (11,653 underlying)
Footnotes (4)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.
  • [F2]The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
  • [F4]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.

Documents

1 file

Issuer

4D Molecular Therapeutics, Inc.

CIK 0001650648

Entity typeother

Related Parties

1
  • filerCIK 0001834021

Filing Metadata

Form type
4
Filed
Jul 11, 8:00 PM ET
Accepted
Jul 12, 5:46 PM ET
Size
13.1 KB